Drug Trial Radar · NCT06472076
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
88
Actual
Start
Jun 10, 2024
Primary completion
Jun 30, 2026
Study completion Aug 30, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- iTeos Therapeutics
- First posted
- Jun 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high NSCLC.
Conditions
- Lung Cancer, Non-Small Cell
Interventions
DostarlimabBiological
Dostarlimab will be administered.
BelrestotugBiological
Belrestotug will be administered.
PembrolizumabBiological
Pembrolizumab will be administered.
PlaceboDrug
Placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to approximately 138 weeks
- Number of Participants with TEAEs or SAEs leading to dose withdrawals or treatment discontinuationTime frame: Up to approximately 138 weeks
Locations
108 sites in 21 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Ocala, Florida
GSK Investigational Site
Honolulu, Hawaii
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Fort Worth, Texas
GSK Investigational Site
Olympia, Washington
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Cipoletti Rio Negro, Argentina
GSK Investigational Site
Ciudad Autonoma de Bueno, Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina
GSK Investigational Site
Córdoba, Argentina
GSK Investigational Site
Florida, Argentina
GSK Investigational Site
Mendoza, Argentina
GSK Investigational Site
Rosario, Argentina
GSK Investigational Site
San Miguel de Tucumán, Argentina
GSK Investigational Site
Hasselt, Belgium
GSK Investigational Site
Mont Gaston, Belgium
GSK Investigational Site
Barretos, Brazil
GSK Investigational Site
Belém, Brazil
GSK Investigational Site
CuritibaPR, Brazil
GSK Investigational Site
Florianópolis, Brazil
GSK Investigational Site
Fortaleza, Brazil
GSK Investigational Site
Londrina, Brazil
GSK Investigational Site
Porto VelhoRondOnia, Brazil
GSK Investigational Site
Salvador, Brazil
GSK Investigational Site
SAo JosE Do Rio PretoSP, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Vitória, Brazil
GSK Investigational Site
Haskovo, Bulgaria
GSK Investigational Site
Plovdiv, Bulgaria
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Chengdu, China
GSK Investigational Site
Hangzhou, China
GSK Investigational Site
Hangzhou, China
GSK Investigational Site
Hefei, China
GSK Investigational Site
Nanjing, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Kuopio, Finland
Showing 40 of 108 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.